Eli Lilly (NYSE:LLY) announced a significant global licensing and research collaboration with Juvena Therapeutics to explore ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

Happy Friday to Barchart readers, everywhere. I don’t know what the weather is like where you live, but here in Halifax, on ...

Shares of Eli Lilly spiked 3.37% on June 10, hitting $800.04 before closing just under that at $799.78. This bump comes as ...

Biotech stocks have long enticed investors with the promise of outsized gains. Amid recent federal policy shifts, two ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...